Alnylam Pharmaceuticals, Inc.
ALNY
$251.56
$8.953.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.92% | -560.61% | 74.39% | 52.18% | -193.31% |
| Total Depreciation and Amortization | -175.99% | 9.50% | -3.12% | 234.11% | -180.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.00% | -41.14% | 106.47% | 8.74% | -54.62% |
| Change in Net Operating Assets | -341.50% | 162.33% | 59.35% | -327.60% | 108.78% |
| Cash from Operations | -316.58% | -64.80% | 252.31% | -173.59% | -108.29% |
| Capital Expenditure | -116.94% | 47.72% | 38.19% | 15.26% | 10.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -68.15% | -162.10% | 176.78% | 75.75% | -3,661.11% |
| Cash from Investing | -74.91% | -189.13% | 150.19% | 71.90% | -2,135.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -66.42% | -18.63% | 413.47% | -16.30% | 24.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -311.93% | -142.01% | -63.38% | 0.01% |
| Cash from Financing | -69.83% | -21.86% | 354.83% | -26.30% | 18.38% |
| Foreign Exchange rate Adjustments | -214.43% | 583.75% | 68.61% | -191.23% | 266.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -201.94% | -54.17% | 320.09% | 40.92% | -158.72% |